Adults who started a GLP-1 weight-loss drug lost weight and then moved less, not more, according to research presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago. [1] The finding upends the assumption that shedding pounds makes movement easier. It does not, at least not on its own.
The stage matters as much as the result. This is a conference abstract, not a peer-reviewed paper, drawn from the National Institutes of Health's All of Us Research Program, which pairs medical records with Fitbit data. Of 1,950 adults with obesity who began a GLP-1 medication, 753 had enough wearable data for the analysis; most were women (78.6%) and the average age was 52.7. [1] Those caveats are the difference between a signal and a verdict.
Within that group the decline was consistent. Average daily step counts fell from 5,047 to 4,487, and time spent in moderate-to-vigorous activity dropped from 28 minutes a day to 22. [1] The largest decreases showed up in men and in people reporting joint or muscle pain; age, heart failure and prior stroke did not change the pattern. The researchers found no evidence that losing weight on the drugs nudged anyone toward more exercise. [1]
That is the part that worries clinicians. Drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) strip lean muscle along with fat, which makes physical activity the main defense for strength and metabolic health. [1] "While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise," said study leader Sajana Maharjan of HSHS St. John's Hospital in Springfield, Illinois. "The findings reinforce that exercise cannot be optional for people taking these medications." [1]
The X feed flattens that nuance in two directions at once — boosters reading the result as a footnote to a miracle, skeptics reading it as proof the drugs make people sedentary. The actual, modest, pre-peer-review finding is narrower and more useful than either: the movement people assume comes free with weight loss does not, so it has to be built in on purpose. The reader task is to pair the injection with deliberate activity, and to treat the muscle as worth protecting.
-- NORA WHITFIELD, Chicago